Pharmacogenetic testing and monitoring of complete blood counts among Veterans newly prescribed thiopurine treatments: a retrospective cohort study

Table 1 Demographics of Veterans newly prescribed thiopurine treatment

Variable	All		Tested^a		Not tested^a		p-value
Variable	Number	Percent	Number	Percent	Number	Percent	p-value
Total	20,524	–	13,535	65.9	7060	34.4
Sex							< 0.05
Female	2748	13.4	1950	14.4	809	11.5
Male	17,776	86.6	11,585	85.6	6251	88.5
Race^b							< 0.05
Asian	159	0.8	125	0.9	34	0.5
American Indian or Alaska Native	136	0.7	90	0.7	46	0.7
Black or African American	3670	17.9	2659	19.6	1019	14.4
Native Hawaiian or Other Pacific Islander	167	0.8	102	0.8	66	0.9
White	15,104	73.6	9763	72.1	5398	76.5
Unknown	1288	6.3	796	5.9	497	7.0
Ethnicity^b							< 0.05
Hispanic or Latino	1113	5.4	796	5.9	323	4.6
Not Hispanic or Latino	18,815	91.7	12,425	91.8	6455	91.4
Unknown	596	2.9	314	2.3	282	4.0
Drug type							< 0.05
Azathioprine	17,655	86.0	11,551	85.3	6104	86.5
Mercaptopurine	3245	15.8	2268	16.8	977	13.8
Thioguanine	47	0.2	22	0.2	25	0.4
Prescriber specialty							< 0.05
Dermatology	659	3.2	541	4.0	118	1.7
Gastroenterology	6666	32.5	5652	41.8	1051	14.9
Hematology	104	0.5	78	0.6	26	0.4
Oncology	117	0.6	87	0.6	30	0.4
Rheumatology	3821	18.6	3019	22.3	802	11.4
Transplant	30	0.1	22	0.2	8	0.1
Other	9235	45.0	4203	31.1	5038	71.4
Test type							–
Genetic or activity	9064	44.2	9064	67.0	–	–
Blood	4489	21.9	4489	33.2	–	–
Not tested	7060	34.4	–	–	7060	100.0

^aTested (i.e., with any genetic or activity tests for TPMT or CBC) and Not Tested have slight overlap due to order of medication given
^bRace and ethnicity information about patients was self-reported and taken from the EHR

ISSN: 2052-3211